Short-Term Effect of Topical Brinzolamide on Human Central Corneal Thickness

Abstract

Purpose

To investigate the effect of short-term brinzolamide application on human central corneal thickness (CCT).

Methods

Seventeen eyes of 16 patients who underwent neodymium:YAG laser posterior capsulotomy were included in the study group. Twenty-two subjects served as controls. Brinzolamide twice daily and fluorometholone four times daily were initiated after the procedure. Corneal thickness was evaluated with an ultrasound pachymetry from the central region. CCT measurements were performed before the procedure, at first day, and at the end of first week.

Results

The mean baseline CCT value was 535.1±37.8 μm. In comparison to the control group (546.4±22.2 μm), there was no statistically significant difference (p=0.248). After brinzolamide instillation, the mean CCT values at first day and at first week was measured as 545.1±40.1 μm and 538.8±39.4 μm, respectively. The difference at first day was statistically significant when compared to the baseline values (p=0.00017). When compared to the control group, no statistically significant difference was observed for the mean CCT values of the first day and first week (p=0.906 and p=0.484, respectively). In the fellow eyes, mean CCT values increased following the dorzolamide instillation (529.3±42.6 μm, 534±41.7 μm, and 533±41.9 μm, respectively). No statistically significant difference was observed between the control group and fellow eye group when compared (p=0.162, p=0.247, p=0.270, respectively).

Conclusions

Brinzolamide may cause a short-term increase in the human CCT, particularly on the first day.

Keywords

Brinzolamide Central corneal thickness

Get full access to this article

View all access options for this article.

References

Wang

T.H.

, Huang

J.Y.

, Hung

P.T.

, Shieh

J.W.

, Chen

Y.F.

Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. J Formos Med Assoc 2004; 103: 369–73.

Unal

, Yücel

, Akar

Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium: YAG laser posterior capsulotomy. J Cataract Refract Surg 2006; 32: 1499–502.

Silver

L.H.

Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998; 126: 400–8.

Almeida

G.C.

, Faria e Souza

S.J.

Effect of topical dorzolamide on rabbit central corneal thickness. Braz J Med Biol Res 2006; 39: 277–81.

Wirtitsch

M.G.

, Findl

, Kiss

, Petternel

, Heinzl

, Drexler

Short-term effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata. Arch Ophthalmol 2003; 121: 621–5.

Lass

J.H.

, Khosrof

S.A.

, Laurence

J.K.

, Horwitz

, Ghosh

, Adamsons

A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. Arch Ophthalmol 1998; 116: 1003–10.

Wilkerson

, Cyrlin

, Lippa

E.A.

Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993; 111: 1343–50.

K.Y.

, Wang

H.Z.

, Hong

S.J.

Cellular cytotoxicity of antiglaucoma drugs in cultured corneal endothelial cells. Kaohsiung J Med Sci 2007; 23: 105–11.

Zhao

J.C.

, Chen

Brinzolamide induced reversible corneal decompensation. Br J Ophthalmol 2005; 89: 389–90.